JNJ

229.87

+1.14%↑

UNH

370.84

+0.14%↑

TMO

478.44

+2.91%↑

ISRG

457.44

+1.12%↑

ABT

90.76

-0.82%↓

JNJ

229.87

+1.14%↑

UNH

370.84

+0.14%↑

TMO

478.44

+2.91%↑

ISRG

457.44

+1.12%↑

ABT

90.76

-0.82%↓

JNJ

229.87

+1.14%↑

UNH

370.84

+0.14%↑

TMO

478.44

+2.91%↑

ISRG

457.44

+1.12%↑

ABT

90.76

-0.82%↓

JNJ

229.87

+1.14%↑

UNH

370.84

+0.14%↑

TMO

478.44

+2.91%↑

ISRG

457.44

+1.12%↑

ABT

90.76

-0.82%↓

JNJ

229.87

+1.14%↑

UNH

370.84

+0.14%↑

TMO

478.44

+2.91%↑

ISRG

457.44

+1.12%↑

ABT

90.76

-0.82%↓

Home・Akciju saraksts・Voyager Therapeutics Inc

Voyager Therapeutics Inc

Slēgts

3.73 2.47

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

3.61

Max

3.7800000000000002

Galvenie mērījumi
By Trading Economics
Ienākumi	466K -27M
Pārdošana	2M 15M
Peļņas marža	-178.834
Darbinieki	141
EBITDA	-2M -29M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt (spēcīgs)
Prognoze 12 mēnešiem	+303.02% upside

Dividendes
By Dow Jones
Nākamie ieņēmumi	2026. g. 4. maijs

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	-4.4M 224M
Iepriekšējā atvēršanas cena	1.26
Iepriekšējā slēgšanas cena	3.73

Tehniskais rādītājs

By Trading Central

Pārliecība

Bearish Evidence

3.17 / 3.4644 Atbalsts un pretestība

Voyager Therapeutics Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 30. apr. 23:08 UTC

Peļņas

Australia's ANZ Warns of Coming Iran Impacts as First-Half Profit Rises -- Update

2026. g. 30. apr. 23:07 UTC

Peļņas

Australia's Warns of Coming Iran Impacts as First-Half Profit Rises -- Update

2026. g. 30. apr. 22:20 UTC

Peļņas

Australia's ANZ Raises 1st Half Profit 9%, Warns of Coming Iran Impacts

2026. g. 30. apr. 23:48 UTC

Tirgus saruna

Nikkei May Rise After Gains on Wall Street -- Market Talk

2026. g. 30. apr. 23:47 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2026. g. 30. apr. 23:47 UTC

Tirgus saruna

Coles's Earnings Views Likely to Edge Down Despite Positives -- Market Talk

2026. g. 30. apr. 23:27 UTC

Tirgus saruna

Liontown Lithium Recovery Expected to Improve -- Market Talk

2026. g. 30. apr. 23:22 UTC

Peļņas

Apple's Incoming CEO John Ternus Makes Appearance as Company Bests Expectations -- Update

2026. g. 30. apr. 23:20 UTC

Tirgus saruna

Wildcat Resources Stands Out Among Lithium Developers -- Market Talk

2026. g. 30. apr. 22:52 UTC

Peļņas

Australia's ANZ Warns of Coming Iran Impacts as First-Half Profit Rises -- Update

2026. g. 30. apr. 22:33 UTC

Peļņas

Zhejiang Expressway: Impairment Loss Weighed on Net >0576.HK

2026. g. 30. apr. 22:32 UTC

Peļņas

Zhejiang Expressway 1Q Net CNY1.31B Vs. Net CNY1.48B >0576.HK

2026. g. 30. apr. 22:32 UTC

Peļņas

Zhejiang Expressway 1Q Rev CNY5.32B Vs. CNY4.36B >0576.HK

2026. g. 30. apr. 22:24 UTC

Iegādes, apvienošanās, pārņemšana

Mineral Resources: Also Reflects Time Needed to Implement Corporate Restructure For JV

2026. g. 30. apr. 22:23 UTC

Iegādes, apvienošanās, pārņemšana

Mineral Resources: Revised Timetable Reflects Time Needed to Get Regulatory Approvals

2026. g. 30. apr. 22:23 UTC

Iegādes, apvienošanās, pārņemšana

Mineral Resources: Now Expects Deal to Complete in 1H FY2027

2026. g. 30. apr. 22:23 UTC

Iegādes, apvienošanās, pārņemšana

Mineral Resources: Executes Key Formal Agreements With Posco on Stake Sale

2026. g. 30. apr. 22:11 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 30. apr. 22:11 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2026. g. 30. apr. 22:11 UTC

Tirgus saruna

Apple Says Demand for Lower-Cost Laptop is Off the Charts -- Market Talk

2026. g. 30. apr. 22:05 UTC

Peļņas

Australia's ANZ Raises 1H Profit 9%, Warns of Coming Iran Impacts

2026. g. 30. apr. 21:57 UTC

Peļņas

ANZ CEO: Increase in Collective Provisions Reflects Risk>ANZ.AU

2026. g. 30. apr. 21:56 UTC

Peļņas

ANZ CEO: Minimal Impact on ANZ's Credit, Capital, Liquidity>ANZ.AU

2026. g. 30. apr. 21:56 UTC

Peļņas

ANZ CEO: No Material Increase in New Cases of Household Hardship>ANZ.AU

2026. g. 30. apr. 21:55 UTC

Peļņas

ANZ CEO: Households Entered Crisis With Generally Strong Balance Sheets>ANZ.AU

2026. g. 30. apr. 21:54 UTC

Peļņas

ANZ CEO: No Material Change in Overall Corporate Borrowing Behavior >ANZ.AU

2026. g. 30. apr. 21:54 UTC

Peļņas

ANZ CEO: Corporate Customers Have Been Building Capital, Liquidity Against Shocks>ANZ.AU

2026. g. 30. apr. 21:53 UTC

Peļņas

ANZ CEO: Much of Iran Conflict's Potential Impact Remains Ahead>ANZ.AU

2026. g. 30. apr. 21:49 UTC

Peļņas

ANZ Group 1H Total Operating Income A$11.20B Vs. A$10.995B>ANZ.AU

2026. g. 30. apr. 21:49 UTC

Peļņas

ANZ Group 1H Customer Deposits A$770.7B Vs. A$756.6B>ANZ.AU

Salīdzinājums

Cenas izmaiņa

Voyager Therapeutics Inc Prognoze

Cenas mērķis

By TipRanks

303.02% augšup

Prognoze 12 mēnešiem

Vidējais 14.67 USD 303.02%

Augstākais 25 USD

Zemākais 8 USD

Pamatojoties uz 8 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Voyager Therapeutics Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

8 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 8 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Voyager Therapeutics Inc — pēdējo 3 mēnešu laikā.

Tehniskais rādītājs

By Trading Central

3.17 / 3.4644Atbalsts un pretestība

Recent bearish events outweigh bullish events.

All events are bearish.

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Voyager Therapeutics Inc

Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial. In addition, the company develops VY-FXN01, which is in preclinical trial to treat friedreich's ataxia; and GBA1 gene replacement to treat parkinson's disease and is in preclinical trial. Further, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc; and Sangamo Therapeutics, Inc. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.